Shots:

• The P-III KEYNOTE-119 study results involves assessing of Keytruda (pembrolizumab- 200mg) as monothx. vs CT (capecitabine/eribulin/gemcitabine/vinorelbine) for the 2L/3L treatment in 622 patients in ratio (1:1) with metastatic triple-negative breast cancer
• The P-III KEYNOTE-119 study demonstrated that it did not meet its 1EPs of OS- safety profile of Keytruda is consistent as no new safety is observed
• Keytruda (pembrolizumab) is mAb targeting PD-1- blocking the interaction b/w PD-1 and its ligands- PD-L1 and PD-L2 thus activating T-lymphocytes affecting both tumor & healthy cells

Ref: Merck | Image: Merck